Coastem Receives Approval for Phase 1 Clinical Trial Plan of Drug Targeting Lou Gehrig's Disease

[Asia Economy Reporter Minji Lee] Corestem announced on the 8th that it has received approval from the Ministry of Food and Drug Safety for a Phase 1 clinical trial plan to evaluate the safety of Neuronata ALJoo (autologous bone marrow-derived mesenchymal stem cells) mixed with artificial cerebrospinal fluid as a suspending agent. This drug targets patients with Lou Gehrig's disease.

The company explained, "Although autologous cerebrospinal fluid was used as an additive for Neuronata-ALJoo, there were difficulties such as patient pain from cerebrospinal fluid collection, medical staff fatigue, and increased ancillary costs. Using artificial cerebrospinal fluid (HTS-FRS) can resolve these issues and is also expected to extend the shelf life of Neuronata-ALJoo."